7-Ethyl-10-hydroxycamptothecin proliposomes with a novel preparation method: Optimized formulation, characterization and in-vivo evaluation

Drug Development and Industrial Pharmacy

Volumn 39, Issue 2, 2013, Pages 393-401

  Wang, Shujun ^a   Ye, Tiantian ^a   Yang, Boyang ^a   Yi, Xiaojun ^a   Yao, Huimin ^b  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b TONGHUA NORMAL UNIVERSITY   (China)

Author keywords

7 ethyl 10 hydroxycamptothecin; Box Behnken design; Differential scanning calorimetry; Intravenous injection; Liposome; Pharmacokinetics; Proliposomes; Stability; Transmission electron microscopy

Indexed keywords

ACETIC ACID; FIRTECAN; GLUCOSE; LIPOSOME; PHOSPHOLIPID; PROLIPOSOME; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; MALE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; RAT; SCANNING ELECTRON MICROSCOPY; TRANSMISSION ELECTRON MICROSCOPY; X RAY DIFFRACTION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOCOMPATIBLE MATERIALS; CALORIMETRY, DIFFERENTIAL SCANNING; CAMPTOTHECIN; DRUG STABILITY; HALF-LIFE; LIPOSOMES; PARTICLE SIZE; RATS; RATS, SPRAGUE-DAWLEY; X-RAY DIFFRACTION;

EID: 84872443002     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.683441     Document Type: Article

References (31)

1. Gallo RC, Whang-Peng J, Adamson RH. (1971). Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin. J Natl Cancer Inst, 46:789-795.
2. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR et al. (1998). Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest, 101:847-854. (Pubitemid 28096082)
3. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G et al. (2001). Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res, 7:2182-2194. (Pubitemid 32751614)
4. Kaneda N, Nagata H, Furuta T, Yokokura T. (1990). Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res, 50:1715-1720. (Pubitemid 20098809)
5. Bencharit S, Morton CL, Howard-Williams EL, Danks MK, Potter PM, Redinbo MR. (2002). Structural insights into CPT-11 activation by mammalian carboxylesterases. Nat Struct Biol, 9:337-342. (Pubitemid 34462550)
6. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ et al. (2000). Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med, 343:905-914.
7. Negoro S, Masuda N, Takada Y, Sugiura T, Kudoh S, Katakami N et al.; CPT-11 Lung Cancer Study Group West. (2003). Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer, 88:335-341. (Pubitemid 36308141)
8. Bodurka DC, Levenback C, Wolf JK, Gano J, Wharton JT, Kavanagh JJ et al. (2003). Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J Clin Oncol, 21:291-297. (Pubitemid 46606158)
9. Sanghani SP, Quinney SK, Fredenburg TB, Davis WI, Murry DJ, Bosron WF. (2004). Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3. Drug Metab Dispos, 32:505-511. (Pubitemid 38535028)
10. Zhang JA, Xuan T, Parmar M, Ma L, Ugwu S, Ali S et al. (2004). Development and characterization of a novel liposome-based formulation of SN-38. Int J Pharm, 270:93-107. (Pubitemid 38077091)
11. Lu Z, Cui TL, Wen FL, Jin, GC, Xin QT, Ying ZZ, Xing L, Hai FL, Xiao KL. (2012). Physical characterization and cellular uptake of propylene glycol liposomes in vitro. Drug Dev Ind Pharm, 37(9):1110-1118.
12. Sumio C, Hirokazu S, Kohei T, Kazuhiro, M. (2011) Efficient drug delivery to lung epithelial lining fluid by aerosolization of ciprofloxacin incorporated into PEGylated liposomes for treatment of respiratory infections. Drug Dev Ind Pharm, 37(4):367-372.
13. Mohammed MM, Hoda AE, Magda WS. (2010). Mucoadhesive liposomes as ocular delivery system: physical, microbiological, and in vivo assessment.
14. Baaran M, Zelihagül D, Ükran Y, Dinç E, Ahmet N. (2011). New perspective for the treatment of Alzheimer diseases: Liposomal rivastigmine formulations. Drug Dev Ind Pharm, 37(7):775-789.
15. Praveen KG, Shikha M, Vipin BG, Mahendra SR, Suresh P, Bhavin AS. (2010). Targeted drug delivery of Rifampicin to the lungs: formulation, characterization, and stability studies of preformed aerosolized liposome and in situ formed aerosolized liposome. Drug Dev Ind Pharm, 36(6):638-646.
16. Xin YL, Song H, Yi J, Li YQ. (2012). Application of liposome encapsulation technique to improve anti-carcinoma effect of resveratrol. Drug Dev Ind Pharm, 38(3):314-322.
17. Wen JC, Qing FL, Xi C, Rong G, Juan L, Yi MW, Guo AL. (2010). Characterization and pharmacokinetics of a novel pirarubicin liposome powder. Drug Dev Ind Pharm 36(10):1186-1194.
18. Langer R. (1998). Drug delivery and targeting. Nature, 392:5-10. (Pubitemid 28215187)
19. Madden TD, Bally MB, Hope MJ, Cullis PR, Schieren HP, Janoff AS. (1985). Protection of large unilamellar vesicles by trehalose during dehydration: retention of vesicle contents. Biochim Biophys Acta, 817:67-74. (Pubitemid 15011680)
20. O'Brien DF, Klingbiel RT, Specht DP, Tyminski PN. (1985). Preparation and characterization of polymerized liposomes. Ann N Y Acad Sci, 446:282-295. (Pubitemid 16238574)
21. Sohail A, Shalini K, Musarrat HW, Mohammed A, Mohammad ZA, Iqbal A, Sushma T, Zeenat IK, Roop KK, Farhan JA. (2012). Development and evaluation of nanosized niosomal dispersion for oral delivery of Ganciclovir. Drug Dev Ind Pharm, 38(1), 84-92.
22. Mohammed SE, Ahmed A, Essam AN, Rawia MK, Dina MM, Ahmed IE, Sameh HAE. (2011). Niosomal encapsulation of the antitubercular drug, pyrazinamide. Drug Dev Ind Pharm, 37(9):1110-1118.
23. Mohammed SE, Ahmed A, Tamer E, Rania MAE, Ahmed AAK. (2011). Niosomes as a potential drug delivery system for increasing the efficacy and safety of nystatin. Drug Dev Ind Pharm, 37(9):1110-1118.
24. Payne NI, Timmins P, Ambrose CV, Ward MD, Ridgway F. (1986). Proliposomes: a novel solution to an old problem. J Pharm Sci, 75:325-329. (Pubitemid 16137097)
25. Katare OP, Vyas SP, Dixit VK. (1991). Proliposomes of indomethacin for oral administration. J Microencapsul, 8:1-7.
26. Xiao YY, Song YM, Chen ZP, Ping QN. (2006). Preparation of silymarin proliposome: A new way to increase oral bioavailability of silymarin in beagle dogs. Int J Pharm, 319:162-168.
27. Xu H, He L, Nie S, Guan J, Zhang X, Yang X et al. (2009). Optimized preparation of vinpocetine proliposomes by a novel method and in vivo evaluation of its pharmacokinetics in New Zealand rabbits. J Control Release, 140:61-68.
28. Fei Xia, Daode Hua, Heyang Jin, Yaping Zhao, Jiamiao Liang. (2010). Preparation of lutein proliposomes by supercritical antisolvent technique. J Food Hydrocolloids, 24:1-8.
29. Chopra S, Patil GV, Motwani SK. (2007). Release modulating hydrophilic matrix systems of losartan potassium: optimization of formulation using statistical experimental design. Eur J Pharm Biopharm, 66:73-82. (Pubitemid 46412965)
30. Chopra S, Motwani SK, Iqbal Z, Talegaonkar S, Ahmad FJ, Khar RK. (2007). Optimisation of polyherbal gels for vaginal drug delivery by Box-Behnken statistical design. Eur J Pharm Biopharm, 67:120-131. (Pubitemid 46991318)
31. Khan S, Ahmad A, Guo W, Wang YF, Abu-Qare A, Ahmad I. (2005). A simple and sensitive LC/MS/MS assay for 7-ethyl-10-hydroxycamptothecin (SN-38) in mouse plasma and tissues: application to pharmacokinetic study of liposome entrapped SN-38 (LE-SN38). J Pharm Biomed Anal, 37:135-142. (Pubitemid 40138726)